Staphylococcus aureus capsule type 8 antibodies provide inconsistent efficacy in murine models of staphylococcal infection

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 254-263

  Cook, James ^a   Hepler, Robert ^a   Pancari, Greg ^a   Kuklin, Nelly ^a   Fan, Hongxia ^a   Wang, Xin Min ^a   Cope, Leslie ^a   Tan, Charles ^a   Joyce, Joseph ^a   Onishi, Jan ^b   Montgomery, Donna ^a   Anderson, Annaliesa ^c   McNeely, Tessie ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c WYETH RESEARCH   (United States)

Author keywords

Antibodies; Capsule polysaccharide; Immune response; Staphylococcus; Vaccine

Indexed keywords

CAPSULAR POLYSACCHARIDE 8 OUTER MEMBRANE PROTEIN COMPLEX CONJUGATE VACCINE; IMMUNOLOGICAL ADJUVANT; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LOW DRUG DOSE; MOUSE; NONHUMAN; OPSONIZATION; OPTIMAL DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURVIVAL RATE;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTERIAL CAPSULES; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICROBIAL VIABILITY; OPSINS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 67349132256     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.6765     Document Type: Article

References (57)

1. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, et al. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32:114-32.
2. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis 2003; 187:1452-9.
3. Farr BM. What to think if the results of the National Institutes of Health randomized trial of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus control measures are negative (and other advice to young epidemiologists): A review and an au revoir. Infect Control Hosp Epidemiol 2006; 27:1096-106.
4. Wisplinghoff H, Bischoff T, Tallent M, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39:1093.
5. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007; 13:1840-6.
6. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298:1763-71.
7. Cunnion KM, Benjamin DK, Hester CG, Frank MM. Role of complement receptors 1 and 2 (CD35 and CD21), C3, C4 and C5 in survival by mice of Staphylococcus aureus bacteremia. J Lab Clin Med 2004; 143:358-65.
8. Verbrugh HA, Peterson PK, Nguyen BYT, Sisson SP, Kim Y. Opsonization of encapsulated Staphylococcus aureus - the role of specific antibody and complement. J Immunol 1982; 129:1681-7.
9. Leijh PCJ, Vandenbarselaar MT, Vanzwet TL, Dubbeldemanrempt I, Vanfurth R. Kinetics of phagocytosis of Staphylococcus aureus and Escherichiacoli by human-granulocytes. Immunol 1979; 37:453-65.
10. Fattom AI, Sarwar J, Basham L, Ennifar S, Naso R. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect Immun 1998; 66:4588-92.
11. Fattom AI, Sarwar J, Ortiz A, Naso R. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun 1996; 64:1659-65.
12. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 1997; 65:4146-51.
13. Xu SL, Arbeit RD, Lee JC. Phagocytic killing of encapsulated and microencapsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1992; 60:1358-62.
14. Han HR, Pak SI, Guidry A. Prevalence of capsular polysaccharide (CP) types of Staphylococcus aureus isolated from bovine mastitic milk and protection of S-aureus infection in mice with CP vaccine. J Vet Med Sci 2000; 62:1331-3.
15. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX (TM), a polysaccharide conjugate vaccine against S-aureus infection: from the lab bench to phase III clinical trials. Vaccine 2004; 22:880-7.
16. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R and others. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Eng J Med 2002; 346:491-6.
17. Edelson S. Nabi under-staphed. In: The Bernstein Report 2005; 8-9.
18. Rupp ME, Holley HP, Lutz J, Dicpinigaitis PV, Woods CW, Levine DP, et al. Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents and Chemother 2007; 51:4249-54.
19. Kuklin NA, Clark DJ, Secore S, Cook J, Cope LD, McNeely T, et al. A novel Staphylococcus aureus vaccine: Iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S-aureus sepsis model. Infect Immun 2006; 74:2215-23.
20. O'Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev 2004; 17:218.
21. Na'was T, Hawwari A, Hendrix E, Hebden J, Edelman R, Martin M, et al. Phenotypic and genotypic characterization of nosocomial Staphylococcus aureus isolates from trauma patients. J Clin Microbiol 1998; 36:414-20.
22. Arbeit RD, Karakawa WW, Vann WF, Robbins JB. Predominance of 2 newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis 1984; 2:85-91.
23. Donnelly JJ, Deck RR, Liu MA. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine. J Immunol 1990; 145:3071-9.
24. Liu MA, Friedman A, Oliff AI, Tai J, Martinez D, Deck RR, et al. A Vaccine Carrier Derived from Neisseria-Meningitidis with Mitogenic Activity for Lymphocytes. Proc Nat Acad Sci USA 1992; 89:4633-7.
25. Vella PP, Marburg S, Staub JM, Kniskern PJ, Miller W, Hagopian A, et al. Immunogenicity of Conjugate Vaccines Consisting of Pneumococcal Capsular Polysaccharide Types-6B, Type-14, Type-19F, and Type-23F and A Meningococcal Outer-Membrane Protein Complex. Infect Immun 1992; 60:4977-83.
26. Ekstrom N, Ahman H, Verho J, Jokinen J, Vakevainen M, Kilpi T, et al. Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial. Infect Immun 2005; 73:369-77.
27. Ekstrom N, Vakevainen M, Verho J, Kilpi T, Kayhty H, FinOM SG. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial. Infect Immun 2007; 75:1794-800.
28. Kilpi T, Ahman H, Jokinen J, Lankinen KS, Palmu A, Savolainen H, et al. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin Infect Dis 2003; 37:1155-64.
29. Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, et al. The Efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type B polysaccharide and Neisseria meningitidis outer membrane protein complex. N Eng J Med 1991; 324:1767-72.
30. Wu YM, Przysiecki C, Flanagan E, Bello-Irizarry SN, Ionescu R, Muratova O, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci USA 2006; 103:18243-8.
31. McNeely TB, Liu X, Bringman T, Donnelly JJ. Effect of individual conjugate dose on immunogenicity of type 6B pneumococcal polysaccharide-N-meningitidis outer membrane protein complex conjugate vaccines in infant rhesus monkeys. Vaccine 2000; 18:2808-16.
32. Jones C. Revised structures for the capsular polysaccharides from Staphylococcus aureus Types 5 and 8, components of novel glycoconjugate vaccines. Carbohydr Res 2005; 340:1097-106.
33. Luong TT, Lee CY. Overproduction of type 8 capsular polysaccharide augments Staphylococcus aureus virulence. Infect Immun 2002; 70:3389-95.
34. Snapper CM, Finkelman FD. Immunoglobulin class switching. In: Paul WE, editor. Fundamental Immunology, 3rd ed. New York: Raven Press, Ltd., 1993: 837-63.
35. Klein DL, Ellis RW. Conjugate vaccines against Streptococcus pneumoniae. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, 2nd ed., New York: Marcel Dekker, Inc., 1997: 503-26.
36. Riddell A, Buttery J. Vaccines against meningococcal disease: current and future technologies. Expert Opin Biol Ther 2001; 1:385-99.
37. Wenger JD, Booy R, Heath PT, Moxon R. Epidemiological impact of conjugate vaccines on invasive disease caused by Haemophilus influenzae Type b. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, Inc., 1997: 489-502.
38. Karakawa WW, Sutton A, Schneerson R, Karpas A, Vann WF. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun 1988; 56:1090-5.
39. Arbeit RD, Nelles MJ. Capsular polysaccharide antigenemia in rats with experimental endocarditis due to Staphylococcus aureus. J Infect Dis 1987; 155:242-6.
40. Goerke C, Wolz C. Regulatory and genomic plasticity of Staphylococcus aureus during persistent colonization and infection. Int J Med Microbiol 2004; 294:195-202.
41. McKenney D, Pouliot KL, Wang Y, Murthy V, Ulrich M, Doring G, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284:1523-7.
42. Cheung AL, Bayer AS, Zhang GY, Gresham H, Xiong YQ. Regulation of virulence determinants in vitro and in vivo in Staphylococcus aureus. FEMS Immunol Med Microbiol 2004; 40:1-9.
43. Liang XD, Zheng L, Landwehr C, Lunsford D, Holmes D, Ji YD. Global regulation of gene expression by ArIRS, a two-component signal transduction regulatory system of Staphylococcus aureus. J Bacteriol 2005; 187:5486-92.
44. Luong T, Sau S, Gomez M, Lee JC, Lee CY. Regulation of Staphylococcus aureus capsular polysaccharide expression by agr and sarA. Infect Immun 2002; 70:444-50.
45. Luong TT, Lee CY. The arl locus positively regulates Staphylococcus aureus type 5 capsule via an mgrA-dependent pathway. Microbiology 2006; 152:3123-31.
46. Pane-Farre J, Jonas B, Forstner K, Engelmann S, Hecker M. The sigma(B) regulon in Staphylococcus aureus and its regulation. Int J Med Microbiol 2006; 296:237-58.
47. Coulter SN, Schwan WR, Ng EYW, Langhorne MH, Ritchie HD, Westbrock-Wadman S, et al. Staphylococcus aureus genetic loci impacting growth and survival in multiple infection environments. Mol Microbiol 1998; 30:393-404.
48. Corbeil LB, Wunderlich AC, Corbeil RR, Mccutchan JA, Ito JI, Braude AI. Disseminated gonococcal-infection in mice. Infect Immun 1979; 26:984-90.
49. Shinefield HR. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? Vaccine 2006; 24:2-9.
50. Gillaspy AF, Lee CY, Sau S, Cheung AL, Smeltzer MS. Factors affecting the collagen binding capacity of Staphylococcus aureus. Infect Immun 1998; 66:3170-8.
51. Luong TT, Newell SW, Lee CY. mgr, a novel global regulator in Staphylococcus aureus. J Bacteriol 2003; 185:3703-10.
52. Fournier JM, Vann WF, Karakawa WW. Purification and characterization of Staphylococcus aureus type-8 capsular polysaccharide. Infect Immun 1984; 45:87-93.
53. Fu J, Bailey FJ, King JJ, Parker CB, Robinett RSR, Kolodin DG, et al. Recent advances in the large-scale fermentation of Neisseria meningitidis group-B for the production of an outer membrane protein complex. BioTechnology 1995; 13:170-4.
54. Leanza WJ, Chupak LS, Tolman RL, Marburg S. Acidic derivatives of homocysteine thiolactone - utility as anionic linkers. Bioconjug Chem 1992; 3:514-8.
55. Pouyani T, Harbison GS, Prestwich GD. Novel hydrogels of hyaluronic acid - synthesis, surface-morphology, and solid-state Nmr. J Am Chem Soc 1994; 116:7515-22.
56. Hamilton MJ, Jones WC. Monoclonal antibody protocols. In: Davis WC, ed Molecular Biology. Totowa: Humana Press, 1995: 17-28.
57. McNeely T, Luo SY, Manger W, Herber W, Schofield T, Tan C, et al. Development of an opsonin inhibition assay for evaluation of complex polysaccharide protective epitopes. Vaccine 2006; 24:1941-8.